Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 136

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 136
---
 healthcare payment systems; |

| • | developments concerning proprietary rights, including patent and litigation matters; |

| • | public concern relating to the commercial value or safety of any of our GH001 and GH002 product candidates or any other product candidates; |

| • | negative publicity or public perception of the use of mebufotenin as a medical treatment; |

| • | financing or other corporate transactions, or the failure to obtain financing or enter into other corporate transactions; |

| • | publication of research reports or comments by securities or industry analysts; |

| • | the trading volume of our ordinary shares on the Nasdaq Global Market (referred to herein as Nasdaq); |

| • | sales of our ordinary shares by us, members of our senior management and directors or our shareholders or the anticipation that such sales may occur in the future; |

| • | general market conditions in the pharmaceutical industry or in the economy as a whole; |

| • | general economic, political, and market conditions and overall market volatility in the United States, the UK or the EU as a result of pandemics or similar events; and |

| • | other events and factors, many of which are beyond our control. |

73 Table of Contents These and other market and industry factors may cause the market price and demand for our securities to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ordinary shares and may otherwise negatively affect the liquidity of our ordinary shares. In addition, pharmaceutical companies have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including as a result of the COVID-19 pandemic. Future sales, or the possibility of future sales, of our securities by existing shareholders could depress the market price of our ordinary shares. Future sales of a substantial number of our ordinary shares, or the perception that such sales will occur, could harm the prevailing market price of our ordinary shares. These sales, or the perception that these sales could occur, also might make it more difficult for us to sell equity securities in the future and at a price that we deem appropriate. Moreover, we have filed a registration statement on Form S-8 with the SEC covering ordinary shares available for future issuance under our equity incentive plans. While such registration statement remains effective, any ordinary shares issued under such plans will be eligible for sale in the public market, subject to compliance with Rule 144, in the case of our affiliates. Sales of a large number of the ordinary shares issued under these